The triple targets have sparked a new revolution in metabolic therapy. The clinical data of Retatrutide (2381089-83-2) is astonishing, leading a wave of industrial layout

Against the backdrop of the continuous iteration and upgrading of the global GLP-1 class drug race, triple-target agonists, with their unique advantage of synergistic enhancement, have emerged as a brand-new breakthrough in the field of metabolic disease treatment. Retatrutide (CAS number:) As a core representative of the triple agonists GCGR (glucagon receptor), GIPR (glucose-dependent insulin-stimulating polypeptide receptor), and GLP-1R (glucagon-like peptide-1 receptor), 2381089-83-2 has demonstrated outstanding clinical efficacy, broad application prospects, and continuous breakthroughs in scientific research value. It has rapidly become the focus of the fields of pharmaceutical research and development, clinical research and chemical production, promoting metabolic health treatment into a brand-new stage of "triple target synergy".
Retatrutide (also known as LY3437943 is an artificially synthesized long-action polypeptide compound. Its chemical formula is C₂₂₁H₃₄₂N₄₆O₆₈, with a molecular weight of approximately 4731.33. The standard purity can reach over 98.0%. It appears as a white powder and is readily soluble in water, with a solubility of up to 33.33 mg/ml (7.04 mm) in vitro. It needs to be ultrasonicated and the pH adjusted to 7. Storage must follow strict conditions: in powder form, it can be stored at -80℃ for 2 years and -20℃ for 1 year; in solvent form, it can be stored at -80℃ for 6 months and -20℃ for 1 month. Throughout the process, it should be stored away from light, sealed and filled with nitrogen to maintain its biological activity. Unlike single-target or dual-target agonists, Retatrutide achieves synergistic regulation of metabolic processes by precisely targeting three key metabolic targets. Its EC50 values for human GCGR, GIPR and GLP-1R are 5.79, 0.0643 and 0.775 nm respectively, and it has excellent binding affinity. It has laid a solid foundation for its outstanding therapeutic effect.

In the field of clinical research, Retatrutide has consistently performed impressively, with multiple clinical trial data fully demonstrating its outstanding advantages in the treatment of metabolic diseases. In the field of obesity treatment, a 48-week phase II obesity study demonstrated that the weight reduction in the 8mg and 12mg dose groups of Retatrutide reached 22.8% and 24.2% respectively, with significantly better weight loss effects than existing dual-target and single-target agonists. In the treatment study of metabolic-related fatty liver disease (MASLD), a randomized Phase IIa clinical trial showed that after 24 weeks of Retatrutide treatment, the relative reduction in liver fat in the 1mg, 4mg, 8mg, and 12mg dose groups reached 42.9%, 57.0%, 81.4%, and 82.4%, respectively. In contrast, the placebo group was only +0.3%. Among them, 79% and 86% of the subjects in the 8mg and 12mg dose groups respectively achieved a normal liver fat content reduction of less than 5%, fully confirming its potential value in the treatment of liver diseases. In addition, Retatrutide has also demonstrated a good hypoglycemic effect in the treatment research of type 2 diabetes. It can regulate insulin and glucagon secretion in a glucose-dependent manner, improve insulin sensitivity, and effectively reduce the risk of hypoglycemia, providing a new option for the comprehensive treatment of metabolic diseases.

In addition to the core research on the treatment of metabolic diseases, the scientific research potential of Retatrutide is continuously being explored, and its application fields are constantly expanding. As a triple-target polypeptide agonist, its unique mechanism of action provides a new entry point for interdisciplinary research. Currently, it has been widely applied in basic research related to obesity and metabolic syndrome. At the same time, it has shown potential value in the preliminary research on the prevention and treatment of complications such as neurodegenerative diseases and cardiovascular diseases, providing new ideas and tools for the research of related diseases. In addition, Retatrutide supports various modification methods such as biotin labeling and fluorescence labeling, which can meet the personalized research needs of scientific research institutions and further promote its popularization and application in the scientific research field.

On the industrial side, with the continuous breakthroughs in Retatrutide's clinical data, the enthusiasm for global market layout has been on the rise, and the industrial development has entered an accelerated period. According to industry research data, the quantifiable global market size of Retatrutide (including research use) is approximately 1.378 billion US dollars in 2025. Among them, the sales volume of research reagents is about 38 kilograms, with an average price of about 340 US dollars /mg, and the production volume of clinical-grade apis is about 3.2 kilograms, with an average price of about 27,000 US dollars /g. It is estimated that by 2032, the global Retatrutide industry's revenue scale will approach 30.93 billion yuan, with a compound annual growth rate of 16.7% from 2026 to 2032. At present, Retatrutide has not been officially approved for marketing, and there is no commercial production capacity worldwide. Only GMP-grade apis for clinical trials and research polypeptide reagents are supplied on a small scale. Eli Lilly, as the original research enterprise, is continuously advancing its clinical progress. Domestic enterprises such as Fujian Jinuo Huopu Biotech and Shaanxi Tianningjian Pharmaceutical Technology have also accelerated their layout. We have promoted the domestic research and development and production process of this product. Some enterprises have achieved relevant technological breakthroughs and can supply high-purity scientific research reagents to meet the market's scientific research demands.

Industry experts say that the rise of Retatrutide (2381089-83-2) marks a leap in the treatment of metabolic diseases from "single target" and "dual targets" to "multi-target synergy". Its innovative mechanism of triple targets not only enhances the therapeutic effect but also broadens the boundaries of metabolic disease treatment. As one of the most promising candidate drugs for the treatment of metabolic diseases at present, the clinical advancement and industrial layout of Retatrutide will further promote the iterative upgrading of peptide drug research and development technology, and at the same time drive the development of related industries such as upstream amino acid derivatives and peptide synthesis resins. In the future, as clinical trials continue to deepen and the commercialization process accelerates, Retatrutide is expected to reshape the treatment landscape of metabolic diseases, bringing new treatment hopes to patients worldwide with obesity, type 2 diabetes, metabolism-related fatty liver disease, etc., while injecting strong impetus into the high-quality development of the pharmaceutical and health industry.

It is reported that the initial supply chain system of Retatrutide has gradually taken shape globally, covering the supply of research reagents, the production of clinical-grade apis, and the matching of upstream raw materials. Relevant enterprises ensure that their products meet international standards through strict quality control systems, providing reliable support for clinical research and scientific research work. Contribute to the continuous progress of global research and treatment of metabolic diseases.